VYNE Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: February 27, 2026
| VYNE Therapeutics Inc. | |
| By: | /s/ David Domzalski |
| David Domzalski | |
| Chief Executive Officer |
KNOW ALL MEN AND WOMEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Domzalski, Tyler Zeronda and Mutya Harsch, and each of them, his or her attorney-in-fact and agent, each with the power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact, or his or her or their substitute or substitutes, may do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Signature | Title | Date |
|---|---|---|
| /s/ David Domzalski | Director and Chief Executive Officer (Principal Executive Officer) | February 27, 2026 |
| David Domzalski | ||
| /s/ Tyler Zeronda | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | February 27, 2026 |
| Tyler Zeronda | ||
| /s/ Sharon Barbari | Director | February 27, 2026 |
| Sharon Barbari | ||
| /s/ Steven Basta | Director | February 27, 2026 |
| Steven Basta | ||
| /s/ Patrick LePore | Director | February 27, 2026 |
| Patrick LePore | ||
| /s/ Elisabeth Sandoval Little | Director | February 27, 2026 |
| Elisabeth Sandoval Little | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.